SCHEMBL550150

SCHEMBL550150

COc1ccc2c(c1)NCC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.50
HTR2A P28223 1/20 0.50
HTR2B P41595 1/20 0.50
HTR5A P47898 2/20 0.46
CPS1 P31327 1/20 0.46
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
DRD2 P14416 2/20 0.43
DRD3 P35462 2/20 0.43
DRD1 P21728 1/20 0.43
DRD5 P21918 1/20 0.43
GFER P55789 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
BCL2 P10415 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
CHRNA7 P36544 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30025932 1.00 HTR2C (0.50) HTR2CHTR2AHTR2BHTR5ACPS1
Acetic Acid SCHEMBL10992625 0.90 CPS1 (0.48) HTR2CHTR2AHTR2BHTR5ACPS1
SCHEMBL30471897 0.89 HRH3 (0.52) HTR2CHTR2AHTR2BHTR5APDE3B
SCHEMBL1395133 0.89 HRH3 (0.52) HTR2CHTR2AHTR2BHTR5APDE3B
SCHEMBL1248073 0.87 PPARG (0.49) HTR2CHTR2AHTR2BHTR5APDE3B
SCHEMBL565913 0.85 DRD2 (0.53) HTR2CHTR2AHTR2BPDE3BPDE3A
SCHEMBL21635492 0.84 EIF2AK2 (0.47) CPS1DRD2GFERSMN1; SMN2HRH3
SCHEMBL5999174 0.83 PDE3B (0.59) HTR2CHTR2AHTR2BHTR5APDE3B
Hydrochloric Acid SCHEMBL2208190 0.83 DRD2 (0.52) HTR2CHTR2AHTR2BPDE3BPDE3A
Hydrochloric Acid SCHEMBL2208192 0.83 DRD2 (0.52) HTR2CHTR2AHTR2BPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117229275-B Novel 2-acetamido thiazole compound and preparation method and application thereof 北京中医药大学 2024-06-18 CN claimed
US-20260085077-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2026-03-26 US disclosed
US-20250304567-A1 PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-10-02 US disclosed
EP-4583977-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-07-16 EP disclosed
EP-4581028-A1 INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Mindset Pharma Inc. (CA) 2025-07-09 EP disclosed
CN-119822910-A Method for catalyzing heterogeneous reduction of nitrogen-containing heterocyclic compound by using magnesium metal 延安大学 2025-04-15 CN disclosed
US-12220421-B2 Inhibitors of C. difficile spore germination THE BOARDS OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS (US) 2025-02-11 US disclosed
WO-2024163852-A1 HISTIDINE KINASE INHIBITORS AS ANTIBACTERIAL AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-08-08 WO disclosed
EP-4398890-A2 INHIBITORS OF C. DIFFICILE SPORE GERMINATION Abel-Santos, Ernesto (US) 2024-07-17 EP disclosed
US-20240199607-A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2024-06-20 US disclosed
WO-1995023141-A1 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS PFIZER INC. (US) 1995-08-31 WO disclosed
US-4496492-A Substituted phenylalkyl compounds THE UPJOHN COMPANY (US) 1985-01-29 US disclosed
US-4431820-A BACTERICIDES; ANTIBIOTICS THE UPJOHN COMPANY (US) 1984-02-14 US disclosed
US-4424365-A 1,2,8,8a-Cyclopropa c!benzo 1,2,-b:-4,3-b'!dipyrrol-4(5H)-ones THE UPJOHN COMPANY (US) 1984-01-03 US disclosed
US-4423230-A REACTING A 5-HYDROXY BENZO(1,2-B: 3,4-B')DIPYRROLE WITH TRIPHENYLPHOSPHINE AND CARBONTETRAHALIDE OR N-IODOSUCCINIMIDE THE UPJOHN COMPANY (US) 1983-12-27 US disclosed
US-4423228-A CYCLIZATION OF ALCOHOL, TRIPHENYLPHOSPHINE, CARBON TETRAHALIDE THE UPJOHN COMPANY (US) 1983-12-27 US disclosed
US-4423229-A Composition of matter and process THE UPJOHN COMPANY (US) 1983-12-27 US disclosed
US-4413132-A Antibiotic CC-1065 indoline intermediates THE UPJOHN COMPANY (US) 1983-11-01 US disclosed
US-4400518-A Composition of matter and process THE UPJOHN COMPANY (US) 1983-08-23 US disclosed
US-4159271-A CYCLIZATION OF A 2-HALOGENOPHENETHYLAMINE IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 1979-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304567-A1 PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE NFKBIA, IKBKG, IKBKB HTR2C 4879/4885HTR2A 4877/4885HTR2B 4875/4885
US-12220421-B2 Inhibitors of C. difficile spore germination CDC37, SI, DAD1 HTR2C 2959/4885HTR2A 3318/4885HTR2B 2591/4885
US-20240199607-A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 HTR2C 2658/4885HTR2A 3085/4885HTR2B 848/4885
US-20260085077-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS TYK2, JAK1, JAK3 HTR2C 799/4885HTR2A 2400/4885HTR2B 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.